Search PubMed⌕ Search

Biomedical subjects

B Bandelow

Publications and source records attributed to B Bandelow.

60 records · Page 4Linked to original sources
PubMed1994

[Recommendations for the use of measuring instruments in clinical anxiety research].

The Arbeitskreis Angstforschung (AKA) brings together investigators active in the field of anxiety research and representatives of anxiety disorder outpatient clinics in German speaking countries. During its regular meetings, the decision was made to develop recommendations for the assessment of anxiety disorder patients in clinical studies. A task force of experts in pharmacological and psychotherapeutic treatments established a consensus of opinion to improve standardisation and comparability of studies originating from different centres. The AKA specifically recommends the following set of variables to be collected in all studies: (1) Demographic data: age, gender, marital status, education, employment, and living situation. (2) DIAGNOSIS: diagnoses should be obtained by clinically experienced personnel with special training in the particular assessment instruments. Structured interviews, according to the current versions of the DSM or ICD classifications are recommended. Published reliability and validity data should be available for the interviews. Examples of specific instruments meeting these criteria are given. (3) Symptoms and course: Data on the course of the disorder should cover onset, type of course, timing of episodes, currently active or in remission, as well as a complete treatment history. In addition, patient self-ratings and observer ratings should be obtained in order to allow comparisons across studies, assess the severity and measure treatment outcome. (4) Disability and restrictions in quality of life: these variables should be assessed by rating scales covering work, social and leisure activities, and family relationships. The AKA expects that these recommendations will be helpful to clinical anxiety researchers. Acceptance of common standards should improve the quality and comparability of pharmacological and psychotherapeutic studies in the complex field of anxiety disorders.

Anti-Anxiety Agents↗
PubMed1992

Depressive syndromes in schizophrenic patients under neuroleptic therapy. ANI Study Group Berlin, Düsseldorf, Göttingen, Munich, Federal Republic of Germany.

Schizophrenic outpatients (= 364) were assigned at random to three different treatment strategies: (1) continuous medication with neuroleptic drugs, (2) intermittent medication with crisis intervention and (3) intermittent medication with early intervention. Depressive syndromes were rated according to three different scales for depressive syndromes (Brief Psychiatric Rating Scale anxious depression factor, Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie/depression, and the self-rating Paranoid Depression Scale) after 1 and 2 years of treatment. No differences in depression scores were found between the three treatment strategies. Comparisons between patients treated with neuroleptic drugs at the time and patients without neuroleptics revealed significantly higher depression scores in the neuroleptics group in most comparisons. No differences were found between patients treated with low versus high potency neuroleptics and between oral versus depot neuroleptics. However, depression correlated with extrapyramidal symptoms.

Administration, Oral↗
PubMed1991

[30 years experience with haloperidol].

Haloperidol, a butyrophenone derivative, was first used 30 years ago and has since become one the most frequently prescribed neuroleptics, employed in the treatment of numerous psychiatric and neurological syndromes. It has a very good antipsychotic effect; its sedative effects are moderate compared against weakly potent neuroleptics, and its vegetative side effects are only slight. In a review of the literature, the data found during the past 30 years are commented upon, such as data on pharmacodynamics, pharmacokinetics, indications, undesirable effects, interactions, dosage, contraindications and precautionary measures - all of them having implications on research on neuroleptics as a whole.

Brain↗
PubMed1990

Depressive syndromes in schizophrenic patients after discharge from hospital. ANI Study Group Berlin, Düsseldorf, Göttingen, Munich.

A total of 364 schizophrenic outpatients who were stabilized for 3 months on continuous neuroleptic therapy after discharge from the hospital were rated according to three different scales for depressive syndromes (Brief Psychiatric Rating Scale anxious depression factor, AMDP/depression, and the self-rating PD-S depression scale). Between 19.5% and 27.5% of the patients were rated as depressed, or 35.7%-42.8%, when mild depressive syndromes were included. There were low, but significant correlations between demographic or life-event data and depression scores on the self-rating scale, whereas fewer correlations were found on the observer ratings. No associations were found between social adjustment and depression. Moderate correlations were found between measures of the apathetic syndrome and depression ratings, while observer ratings showed higher correlations than the self-rating. High depression scores, especially in the observer ratings, correlated with scales for global psychopathological assessment (CGI, GAS). There were significant correlations between extrapyramidal rigidity and observer rating depression scores, whereas the total amount of neuroleptics given had no influence. These results are interpreted on the basis of hypotheses about depressive syndromes in schizophrenia.

Antipsychotic Agents↗